Hormonal strategy to reduce suckled beef cow handling for timed artificial insemination with sex-sorted semen.

Two experiments were conducted to assess a hormonal strategy developed to reduce animal handling for timed artificial insemination (TAI) with sex-sorted semen. Four-hundred ninety-one (491) suckled beef cows received a progesterone (P4) intravaginal device and 2 mg intramuscular (im) injection of estradiol benzoate (EB) on a randomly chosen day of the estrus cycle (Day 0) in Experiment 1. Cows were treated with 500 µg of sodic cloprostenol (PGF2α) and with 300 IU of eCG at P4 device removal (Day 8); these cows were also randomly assigned to receive 1 mg of estradiol cypionate (EC) administered at P4 device removal (treatment EC-0h) or 1 mg of EB 24 h after P4 device removal (treatment EB-24h). Both treatments were timed inseminated (TAI) with sex-sorted semen 60 h after P4 device removal. Cows treated with EC-0h presented higher pregnancy rate per AI (P/AI) [45.0% (113/251)] than the ones treated with EB-24h [35.4% (85/240); P = 0.03)]. A subset of cows (n = 26) were subjected to ultrasound examination every 12 h after P4 device removal for 96 h in the row in order to determine the time of ovulation. Similar interval between device removal and ovulation was recorded for EB-24h = 70.0 ±â€¯2.9 h vs. EC-0h = 66.0 ±â€¯2.8 h (P = 0.52). Five-hundred ninety-one (591) cows were subjected to the same synchronization protocols and treatments (EC-0h or EB-24h). In addition, they were randomly assigned to a 2 × 2 factorial arrangement aiming at determining the effects of treatment with estradiol (EC-0h vs. EB-24h) and of semen type (Sex-sorted vs. Non-sex-sorted semen). All animals were timed inseminated 60 h after P4 device removal. There was no interaction (P = 0.07) between the ovulation inducer and semen type. The EC protocol led to greater P/AI than EB (P = 0.03). Greater (P = 0.01) P/AI was achieved through treatments with non-sex-sorted semen rather than with sex-sorted semen [sex-sorted (EB-24h = 49.0%; EC-0h = 51.0%) vs. non-sex-sorted semen (EB-24h = 52.4%; EC-0h = 68.2%)]. Therefore, EC administered at P4 device removal resulted in greater P/AI. Furthermore, the EC-0h protocol allowed reducing suckled beef cow handing for timed artificial insemination with sex-sorted semen.

Supplementation of prepartum dairy cows with ß-carotene.

The prepartum supplementation of dairy cows with ß-carotene was evaluated. Cows were blocked by parity and expected calving date and assigned to a treatment: ß-carotene (1.2 g/cow per d) or control (no supplementation). The same total mixed ration batch was offered to all cows, and ß-carotene was top dressed to individual cows once per day. The data set contained 283 Holsteins that received a treatment for >14 d (29.1±6.9 d). Frequency distributions were analyzed with the GENMOD procedure of SAS using logistic regression for binomial data. Continuous variables were analyzed with the MIXED procedure of SAS. Within parity, nonparametric estimates of the survivor function for reproductive variables were computed using the product-limit method of the Kaplan-Meier method with the LIFETEST procedure of SAS. Plasma ß-carotene concentration before supplementation was similar between supplemented and nonsupplemented cows (2.99µg/mL) and peaked at 3.26±0.175µg/mL on d -15±2.4 precalving for supplemented cows (2.62±0.168µg/mL for control). Colostrum density, milk yield, and milk composition were similar between treatments. ß-Carotene tended to increase milk protein content from 2.90 to 2.96% and to decrease the proportion of primiparous cows with a milk fat to protein ratio >1.5 from 22.6 to 6.4%. The proportion of primiparous and multiparous cows with difficult calving, metritis, progesterone >1 ng/mL at 21 d and at 42 d in lactation, % conception at first service, and % pregnancy at 90 and 150 d in lactation were similar between treatments. A trend for decreased incidence of somatic cell count >200,000 cells/mL was present in multiparous cows supplemented with ß-carotene (38.9% vs. 28.1%). ß-Carotene was associated with a reduction in the proportion of multiparous cows with retained placenta 12 h postpartum from 29.9 to 21.7%; time of placenta release was 392 min (340 to 440) for ß-carotene and 490 min (395 to 540) for control (median and 95% confidence interval). For primiparous cows, placenta release was not affected by ß-carotene (incidence was 15.4%). The intervals from calving to first estrus, to first service, and to conception were not affected by ß-carotene supplementation in either parity. However, independent of treatment, cows with improved reproductive efficiency had increased postpartum ß-carotene concentration in plasma. The prepartum supplementation of ß-carotene increased plasma concentration around calving. No response in milk yield or reproductive performance was detected. Beta-carotene supplementation was associated with a lower incidence of retained placenta in multiparous cows.

Plasma anti-mullerian hormone: an endocrine marker for in vitro embryo production from Bos taurus and Bos indicus donors.

The aim of this study was to evaluate the association between plasma anti-mullerian hormone (AMH) concentration and in vitro embryo production (IVP) from Bos taurus (Holstein) and Bos indicus (Nelore) donors. A total of 59 Holstein (15 prepubertal heifers aged 8-10 mo, 15 cyclic heifers aged 12-14 mo, 14 lactating cows, and 15 nonlactating cows) and 34 Nelore (12 prepubertal heifers aged 10-11 mo, 10 prepubertal heifers aged 21-23 mo, and 12 cyclic heifers aged 24-26 mo) females were enrolled. All females underwent an ovum pick-up (OPU), without previous synchronization of the follicular wave, and IVP procedure. Immediately before the OPU procedure, blood samples were collected for subsequent AMH determination. A positive correlation was observed between the plasma AMH and number of in vitro embryos produced from Holstein (r = 0.36, P < 0.001) and Nelore (r = 0.50, P = 0.003) donors. For additional analyses, donors within each genotype were classified into 1 of 2 AMH categories (low or high) according to the average AMH concentration for each genotype. The results revealed that females classified as having high AMH presented a greater number of visible aspirated follicles (Holstein: 20.9 ± 1.5 vs 13.6 ± 0.9, P < 0.0001; Nelore: 54.3 ± 6.1 vs 18.6 ± 2.1, P < 0.0001) and a greater number of recovered cumulus-oocyte complexes (Holstein: 17.3 ± 1.5 vs 9.0 ± 0.9, P < 0.0001; Nelore: 45.3 ± 6.4 vs 13.4 ± 1.7, P < 0.0001). However, there was no difference in the blastocyst production rate (Holstein: 20.6% ± 4.0% vs 19.8% ± 4.2%, P = 0.60; Nelore: 33.7% ± 6.5% vs 27.4% ± 5.5%, P = 0.41, high and low AMH, respectively). Moreover, donors classified as having high AMH yielded a greater number of embryos produced per OPU (Holstein: 3.0 ± 0.7; Nelore: 7.0 ± 1.7) compared with those classified as having low AMH (Holstein: 1.2 ± 0.3, P = 0.04; Nelore: 2.2 ± 0.5, P = 0.007). In conclusion, although the plasma AMH concentration did not alter the ability of the cumulus-oocyte complex to reach the blastocyst stage, the AMH concentration in plasma can be an accurate endocrine marker for the in vitro embryo yield from either B. taurus (Holstein) or B. indicus (Nelore) donors. Therefore, AMH is a promising tool to enhance the overall efficiency of OPU-IVP programs in the field as a selective criterion for high embryo producing donors.